Search

Andrew Mark Scharenberg

from Seattle, WA
Age ~61
Get Report
Also known as:
Andrew M Scharenberg, Andrew M Sharenberg, Andrew M Schrenber, Andrew G
Phone and address:
1222 Norcross Way, Seattle, WA 98177
(206) 362-8724
Connected to:
William R Scharen, 62Jessie M Schares, 43Kelsey J Scharer, 45Robert A Scharer, 84Ronald R Scharer, 70Ryan L Scharer, 48Christine R Scharett, 55Joseph L Scharett, 82Allison M Scharf, 50Ann H Scharf, 80

Andrew Scharenberg Phones & Addresses

  • 1222 Norcross Way, Seattle, WA 98177 (206) 362-8724
  • 12 Skyview Rd, Lexington, MA 02420
  • Kensington, MD
  • Bethesda, MD
  • Bloomington, IN
  • West Lafayette, IN
  • Chapel Hill, NC

Work

Company: University Washington Physical IMM Address: 307 Westlake Ave N Suite 300, Seattle, WA 98109 Phones: (206) 987-4385

Education

School / High School: University Of North Carolina, Chapel Hill, School Of Medicine 1990

Languages

English • Spanish

Awards

Healthgrades Honor Roll

Ranks

Certificate: Pediatrics, 2001

Emails

a***[email protected]

Specialities

Pediatrics

Professional Records

Medicine Doctors

Andrew Scharenberg Photo 1

Dr. Andrew Scharenberg, Seattle WA - MD (Doctor of Medicine)

View page
Specialties:
Pediatrics
Address:
University Washington Physical IMM
307 Westlake Ave N Suite 300, Seattle, WA 98109
(206) 987-4385 (Phone)

4800 Sand Point Way Ne, Seattle, WA 98105
(206) 987-4385 (Phone)
Certifications:
Pediatrics, 2001
Awards:
Healthgrades Honor Roll
Languages:
English
Spanish
Education:
Medical School
University Of North Carolina, Chapel Hill, School Of Medicine
Graduated: 1990
Medical School
University Of Nc Hosps
Graduated: 1990
Andrew Scharenberg Photo 2

Andrew M. Scharenberg

View page
Specialties:
Immunology
Work:
Seatlle Childrens Hospital Immunology Clinic
4800 Sand Pt Way NE, Seattle, WA 98105
(206) 987-4385 (phone), (206) 987-3946 (fax)
Education:
Medical School
University of North Carolina School of Medicine at Chapel Hill
Graduated: 1990
Conditions:
Infectious Mononucleosis
Meningitis
Languages:
English
Description:
Dr. Scharenberg graduated from the University of North Carolina School of Medicine at Chapel Hill in 1990. He works in Seattle, WA and specializes in Immunology. Dr. Scharenberg is affiliated with Seattle Childrens Hospital and University Of Washington Medical Center.
Andrew Scharenberg Photo 3

Andrew Mark Scharenberg, Seattle WA

View page
Specialties:
Pediatrics
Pediatric Clinical & Laboratory Immunology
Allergy & Immunology
Work:
Seattle Children's Hospital
4800 Sand Point Way NE, Seattle, WA 98105
Education:
University of North Carolina (1990)

Resumes

Resumes

Andrew Scharenberg Photo 4

Andrew Scharenberg

View page
Andrew Scharenberg Photo 5

Professor Of Pediatrics And Immunology At University Of Washington

View page
Location:
Greater Seattle Area
Industry:
Research
Experience:
University of Washington (Educational Institution; Higher Education industry): Professor of Pediatrics and Immunology,  (2000-Present) 

Business Records

Name / Title
Company / Classification
Phones & Addresses
Andrew Mark Scharenberg
Andrew Scharenberg MD
Allergist · Pediatric Allergist · Pediatrician
4800 Sand Pt Way NE, Seattle, WA 98105
(206) 987-2000
Andrew M. Scharenberg
Pediatric Immunologist
Pediatric Immunology
Medical Doctor's Office
307 Westlake Ave N, Seattle, WA 98109

Publications

Us Patents

Nucleic Acids Encoding A Domain-Containing Polypeptide

View page
US Patent:
8153400, Apr 10, 2012
Filed:
Apr 26, 2000
Appl. No.:
09/958184
Inventors:
Andrew M. Scharenberg - Seattle WA, US
Assignee:
Beth Israel Deaconess Medical Center, Inc. - Boston MA
International Classification:
C12N 15/09
US Classification:
435 692, 435 6, 435 18, 435 691, 530350
Abstract:
The invention pertains to nucleic acids encoding a mutT domain-containing polypeptide, including fragments and biologically functional variants thereof. The invention also pertains to therapeutics and diagnostics involving the foregoing polypeptide and nucleic acids and agents that bind the foregoing polypeptide and nucleic acids. The invention also pertains to the identification of a novel mutT domain in human TrpC7, a polypeptide previously described as a putative calcium ion channel. Accordingly, the invention also pertains to methods and compositions for identifying agents useful modulating mutT domain-mediated calcium or other ion transport in cells expressing a polypeptide comprising a mutT domain and a calcium or other ion channel.

Compositions And Methods For Modulating Calcium Flux, Glucose Homeostasis And Apoptosis

View page
US Patent:
8440638, May 14, 2013
Filed:
Jul 20, 2005
Appl. No.:
11/658069
Inventors:
John M. Denu - McFarland WI, US
Andrew M. Scharenberg - Seattle WA, US
Assignee:
Wisconsin Alumni Research Foundation - Madison WI
University of Washington - Seattle WA
International Classification:
A61K 31/7076
A61K 31/7052
A61K 31/455
C07H 19/167
C07H 19/20
C07H 19/173
US Classification:
514 45, 514 46, 514 47, 514 42, 514356, 536 221, 536 276, 435375
Abstract:
Compositions and methods are disclosed which are effective for modulating glucose homeostasis, calcium ion flux and cell death in target cells.

Nucleic Acids Encoding A Mut-T Domain-Containing Polypeptide

View page
US Patent:
8614300, Dec 24, 2013
Filed:
Mar 9, 2012
Appl. No.:
13/416854
Inventors:
Andrew M. Scharenberg - Seattle WA, US
Assignee:
Beth Israel Deconess Medical Center, Inc. - Boston MA
International Classification:
C07K 16/40
C07K 16/46
C07K 16/00
G01N 33/53
US Classification:
53038826, 53038815, 5303881, 5303879, 5303873, 5303871, 435 71
Abstract:
The invention pertains to nucleic acids encoding a mutT domain-containing polypeptide, including fragments and biologically functional variants thereof. The invention also pertains to therapeutics and diagnostics involving the foregoing polypeptide and nucleic acids and agents that bind the foregoing polypeptide and nucleic acids. The invention also pertains to the identification of a novel mutT domain in human TrpC7, a polypeptide previously described as a putative calcium ion channel. Accordingly, the invention also pertains to methods and compositions for identifying agents useful in modulating mutT domain-mediated calcium or other ion transport in cells expressing a polypeptide comprising a mutT domain and a calcium or other ion channel.

Antibodies

View page
US Patent:
20070031404, Feb 8, 2007
Filed:
Jun 16, 2006
Appl. No.:
11/454636
Inventors:
Andrew Scharenberg - Seattle WA, US
Assignee:
Beth Israel Deaconess Medical Center, Inc. - Boston MA
International Classification:
A61K 39/395
C07K 16/44
US Classification:
424141100, 530388150
Abstract:
Nucleic acids encoding SOC/CRAC calcium channel polypeptides, including fragments and biologically functional variants thereof and encoded polypeptides are provided. The nucleic acids and polypeptides disclosed herein are useful as therapeutic and diagnostic agents. Agents that selectively bind to the foregoing polypeptides and genes also are provided.

Compositions And Methods Comprising The Use Of Cell Surface Displayed Homing Endonucleases

View page
US Patent:
20090162937, Jun 25, 2009
Filed:
Mar 27, 2007
Appl. No.:
12/295201
Inventors:
Andrew M. Scharenberg - Seattle WA, US
Assignee:
CHILDREN'S HOSPITAL & REGIONAL MEDICAL CENTER - Seattle WA
International Classification:
C12N 15/87
C12N 9/24
C40B 30/04
C40B 40/02
US Classification:
435456, 435455, 435200, 506 9, 506 14
Abstract:
According to particular exemplary aspects, DNA target site binding and cleavage properties of native, variant or modified homing endonucleases (HE) (e.g., LAGLIDAG (LHE), HNH, His-Cys Box, GIY-YIG, I-SspI-type, and fusions, muteins or variants thereof) in solution are recapitulated on the cell surface (e.g., as assessed by flow cytometric analysis) to provide for novel cells expressing one or more cell surface HEs (e.g., expressing one or more HE binding and/or cleavage specificities), novel cell libraries, and high-throughput methods for assessing target site binding, target site cleavage. The rapid analysis of HE and LHE-DNA interactions on the cell surface with concurrent sorting options provides for high-throughput library screening affording rapid identification, analysis and isolation of novel HEs or LHEs having novel sequence specificities. Such novel sequence specificities, obtained by said methods provide novel methods for introducing targeted DNA-strand cleavage events, and novel chromatin immunoprecipitation methods (CHIP methods).

Coupling Endonucleases With End-Processing Enzymes Drives High Efficiency Gene Disruption

View page
US Patent:
20120276074, Nov 1, 2012
Filed:
Feb 24, 2012
Appl. No.:
13/405183
Inventors:
Andrew M. Scharenberg - Seattle WA, US
Michael T. Certo - Seattle WA, US
Kamila S. Gwiazda - Seattle WA, US
Assignee:
SEATTLE CHILDREN'S RESEARCH INSTITUTE - Seattle WA
International Classification:
C12N 9/96
A61P 37/02
A61P 31/18
C12N 15/90
A61K 38/46
US Classification:
424 942, 435188, 435462, 424 946
Abstract:
The present disclosure relates to the co-expression of an endonuclease with an end-processing enzyme for the purpose of enhanced processing of the polynucleotide ends generated by endonuclease cleavage.

Methods For Engineering Allogeneic And Immunosuppressive Resistant T Cell For Immunotherapy

View page
US Patent:
20130315884, Nov 28, 2013
Filed:
May 13, 2013
Appl. No.:
13/892805
Inventors:
Roman Galetto - Paris, FR
Agnès Gouble - Paris, FR
Stéphanie Grosse - Saint-Cyr sur Morin, FR
Cécile Mannioui - Villiers sur Marne, FR
Laurent Poirot - Paris, FR
Andrew Scharenberg - Seattle WA, US
Julianne Smith - Le Plessis Robinson, FR
International Classification:
A61K 35/14
US Classification:
424 9371, 435375
Abstract:
Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

Compositions Of The Soc/Crac Calcium Channel Protein Family

View page
US Patent:
7063959, Jun 20, 2006
Filed:
Dec 20, 1999
Appl. No.:
09/869486
Inventors:
Andrew Scharenberg - Seattle WA, US
Assignee:
Beth Israel Deaconess Medical Center, Inc. - Boston MA
International Classification:
C12P 21/06
A61K 38/17
C07K 1/00
C07H 21/04
C07H 21/02
US Classification:
435 691, 530350, 536 231, 536 235, 514 12, 514 2
Abstract:
Nucleic acids encoding SOC/CRAC calcium channel polypeptides, including fragments and biologically functional variants thereof and encoded polypeptides are provided. The nucleic acids and polypeptides disclosed herein are useful as therapeutic and diagnostic agents. Agents that selectively bind to the foregoing polypeptides and genes also are provided.
Control profile
Andrew Mark Scharenberg from Seattle, WA, age ~61 Get Report